- Home
- GRF vs INMB Comparison
GRF vs INMB Comparison
Compare GRF & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | INMB |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 37.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GRF | INMB |
|---|---|---|
| Price | $9.97 | $1.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 3.8K | ★ 279.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.60 | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $9.50 | $1.09 |
| 52 Week High | $11.85 | $11.64 |
Technical Indicators
Market Signals| Indicator | GRF | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 54.75 |
| Support Level | $9.96 | $1.37 |
| Resistance Level | $10.13 | $1.52 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 29.33 | 62.69 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.